July 2024 FDA Recall Drug by Sun Pharmaceutical Industries Inc
D-0582-2024 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Sun Pharmaceutical Industries Inc on July 2, 2024 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0582-2024

Reason for Recall
CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.
Initiated
07-02-2024
Reported
07-10-2024
Quantity
2088 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
SUN PHARMACEUTICAL INDUSTRIES INC
Nationwide in the USA
Decitabine for Injection 50mg per vial, For intravenous infusion only Cytotoxic Agent, Sterile, Rx Only, Single-Dose Vial, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 47335-361-40.

Batch or Lot Expiration Information

Lot# HAD2964A, Exp 7/31/2024